drugset / Trial / NCT03324555
Study of ORIC-101 in Healthy Adult Subjects
NaSingle-groupOpen-labelTreatment
Summary
ORIC-GR-17001 is an open-label, single center, non-randomized, single ascending dose study in healthy male subjects and healthy female subjects of non-child bearing potential. In this study, ORIC-101 will be administered as single-ascending oral doses. The primary objective is to characterize the safety and tolerability of oral ORIC-101.
Timeline
- Start
- 2017-10-19
- Primary completion
- 2017-12-18
- Completion
- 2017-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORIC-101 | Small molecule | — | Oral |
Indications
No indication recorded.